A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

NCT02752035 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

183

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

Interventions

DRUG: gilteritinib
DRUG: azacitidine

Sponsor

Astellas Pharma Global Development, Inc.